Editor-in-Chief & Deputy Editor 2019-2021

 

Editor-in-Chief:

Nicolas LANTHIER

 

Deputy Editor:

Tim VANUYTSEL

 

 

Sponsors & Partners



Acta Gastroenterologica Belgica is supported by grants from its major sponsors

 

Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma

 

 

 

 

 

 

Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies


 

 

 

 

 

SRBGE

 

Observation of combined/optimized therapy of Lamivudine and Adefovir Dipivoxyl for hepatitis B- induced decompensated cirrhosis with baseline HBV DNA>1,000 IU/mLObstructive jaundice at the age of 24

Observational survey of NSAID-related upper gastro-intestinal adverse events in Belgium

Price: €10,00








(Acta gastroenterol. belg., 2002, 65, 65-73)

April-June Volume 65, fasc. 2

Observational survey of NSAID-related upper gastro-intestinal adverse events in Belgium

J. Belaiche, A. Burette, M. De Vos, E. Louis, M. Huybrechts, M. Deltenre. On behalf of the Belgian Study Group of NSAID-GI complications. (1) Department of Gastroenterology, CHU Sart-Tilman, Liège, Belgium ; (2) Gastroenterology Dept. Clinic Edith Cavell, nouvelle Clinique de la Basilique, Brussels,Belgium ; (3) Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium ; (4) AstraZeneca pharmaceuticals, Brussels, Belgium ; (5) Gastroenterology, Dept. CHU Brugmann, ULB/VUB, Brussels, Belgium.

Objectives : To evaluate the impact of NSAID use on current routine upper GI endoscopy (UGIE) and to compare the lesions found in NSAID users and non-users. Methods : Participating gastroenterologists consecutively documented outpatients with and without suspicion of bleeding, referred for upper gastrointestinal endoscopy. Patient characteristics, presence of risk factors, NSAID use and endoscopic findings were reported on standard data collection forms. Main results : A total of 2685 non-bleeding and 159 bleeding patients were enrolled within a time period of 2 months. NSAID therapy was present in 20% of the non-bleeding patients and at least 9% of referrals for endoscopy were directly related to suspected NSAID adverse events. Nearly half of acute bleeding patients (42%) were NSAID users, including aspirin for cardioprevention. Warning digestive symptoms prior to acute bleeding were frequently absent (56%). Oesophagitis was the main endoscopic diagnosis (51% of patients). Gastroduodenal (GD) ulcer was significantly more frequent in NSAID users, whereas oesophagitis and bleeding oesophageal varices were more frequent among non-users. Analysis of odds ratio’s demonstrated NSAID use to significantly increase the risk for gastric ulcer in the whole patient group (OR = 2.73 ; 95% confidence interval (CI) : 1.98- 3.77 ; p < 0.001) and, in addition, for duodenal ulcer in the elderly (>65y) subgroup (OR = 2.91 ; 95% CI : 1.52-5.59 ; p < 0.05). Conclusions : This survey confirms the high incidence of GD ulcers in NSAID users and the risk for serious gastrointestinal complications, often occurring without warning symptoms. It underlines the impact of NSAID use on the routine endoscopy load, the necessity of careful selection of patients for NSAID prescriptions and the need for gastropreventive measures, particularly in elderly patients and patients associating multiple risk factors.